Obina

Researchers are evaluating whether the smallpox vaccine can reduce the number of secondary monkeypox cases and decrease symptom severity in people exposed to monkeypox. This phase 4, pragmatic, adaptive, multi-site cluster randomized controlled trial focuses on households where one or more individuals have confirmed monkeypox infection. The study aims to compare outcomes between vaccinated and unvaccinated groups within these households. Participants will be assigned by household to receive either a single dose of the Bavarian Nordic smallpox vaccine or a single dose of the typhoid vaccine as a control at the start of the study. The vaccination is given once at baseline, and households are monitored to assess the effect of the vaccine on preventing monkeypox and reducing symptoms. During the 8-week study period, researchers will track confirmed monkeypox cases using RT-PCR tests and measure symptom severity. Participants will be observed for the development of monkeypox and the progression of symptoms. Safety and effectiveness outcomes will be collected to understand the vaccine's impact as post-exposure prophylaxis in household contacts of monkeypox cases.